979 – Cabotegravir LA for PrEP: Progress in HIV Prevention From 3 Years of OPERA Data
Background Cabotegravir long-acting (CAB LA) is the first FDA-approved injectable for HIV pre-exposure prophylaxis (PrEP). This analysis evaluated CAB-LA usage, adherence to its dosing schedule, and the incidence of HIV acquisition in routine clinical care. Methods Adults without HIV receiving ≥1 CAB LA PrEP injection between 21Dec2021 and 30Jun2024 in the US OPERA cohort were followed…